-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteinyl-(S)-seryl-(S)-lysyl-(S)-lysyl-(S)-lysyl-(S)-lysine
[Pam3CysSer(Lys)4] on several functions of human platelets. Pam3CysSer(Lys)4 led to the aggregation of platelets and induced the secretion of serotonin with an effectiveness similar to thrombin. These cellular effects of Pam&ZysSer(Lys) 4 were concentration dependent, being half maximal at 2-3 PM and maximal at lo-30 PM. Another lipopeptide also induced platelet aggregation and serotonin secretion but was less potent and less effective than Pam&ysSer(Ly& The lipid moiety and the peptide moiety of Pam$ysSer(Lys)4 alone were without any effect. Lipopeptides also stimulated tyrosine phosphorylation of several proteins with molecular masses similar to those found to be tyrosine phosphorylated in response to thrombin, and Pam3-CysSer(Lys) 4 led to an increase in the cytosolic calcium concentration.
All studied responses of platelets to lipopeptides were inhibited by the prostacyclin receptor agonist cicaprost. Taken together, our data show that lipopeptides are effective activators of human platelets and that this activation is susceptible to the action of physiological platelet inhibitors. platelet aggregation; tyrosine phosphorylation; serotonin secretion; bacterial lipoprotein; lipopeptides;
N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteinyl-(S)-seryl-(S)-lysyl-(S)-lysyl-(S)-lysyl-(S)-lysine
UNDER NORMAL CONDITIONS, human platelets circulate in the blood as resting cells. Platelets can be activated by a variety of stimuli. Activation of platelets ultimately leads to their aggregation and to the release of preformed mediators such as serotonin. Many of the biochemical events that accompany their activation process have been well described (for review see Refs. 16, 30). The initial response of platelets toward many activating stimuli involves the rapid hydrolysis of inositol phospholipids with the release of inositol 1,4,5trisphosphate, a consecutive increase in cytosolic calcium concentration ([Ca'+]i), and activation of protein kinase C. More recently, rapid changes in tyrosine phosphorylation of platelet proteins have been recognized to be an important early mechanism during platelet activation (29).
The outer membrane of gram-negative bacteria contains lipoprotein as one of its major components (5). Bacterial lipoprotein carries a characteristic moiety at the NH2-terminus, consisting of one amide-linked and two ester-linked fatty acids attached to S-(2,3-dihydroxypropyl)-cysteine. Synthetic lipopeptide analogues of the NH2-terminus of bacterial lipoproteins are activators of lymphocytes (3), macrophages (12), and neutrophils (28). No cellular receptor for lipoprotein or synthetic lipopeptide analogues has so far been described, and the molecular mechanisms involved in the cellular activation by lipopeptides are not well understood. In macrophages, lipopeptides have been shown to lead to an increase in [Ca2+]i (13), and activation of the membranebound form of protein kinase C was observed in B-cells (4). In myeloid cells, lipopeptides are effective stimulators of tyrosine phosphorylation (2 1).
To extend the knowledge about the biological actions of lipopeptides, we studied the effect of synthetic lipopeptides on several functions of human platelets and found them to be very effective platelet activators.
MATERIALS AND METHODS

MateriaZs.
Lipopeptides Venous blood was collected from healthy drug-free volunteers and anticoagulated with 6 mM citric acid-12 mM sodium citrate. Platelet isolation was carried out at room temperature.
Platelet-rich plasma was obtained by centrifugation of whole blood for 20 min at 200 g. Platelet-rich plasma was adjusted with citrate buffer to pH 6.5 and centrifuged again two times for 15 min at 200 g to remove contaminating cells. Thereafter, platelets were pelleted by centrifugation for 10 min at 700 g and washed once in (in mM) 23.5 glucose, 133 NaCl, and 6 citric acid-12 sodium citrate. Washed platelets were carefully resuspended in Hanks' buffer devoid of calcium [in mM: 138 NaCl, 6 KCl, 1 MgC12, 1 Na2HP04, 5 NaHC03, and 5.5 glucose, as well as 0.1% (wt/vol) bovine serum albumin and 20 mM N-2-hydroxyethylpiperazine-2V'-2-ethanesulfonic acid-NaOH (pH 7. 
RESULTS
Incubation
of human platelets with 30 PM PamsCysSer(Lys)d led to the rapid aggregation of platelets (Fig. IA) . Pam3CysSer(Lys)4 was as effective as was 1.5 U/ml thrombin. Although Pam&ysSer(Ly&in-duced aggregation was maximal after -3-4 min, aggregation induced by thrombin did not reach a maximum until 10 min. The lipopeptide Pam$ysAlaGly (30 PM), which differs in its peptide moiety from Pam$ysSer(Ly&, also induced platelet aggregation. However, aggregation of platelets in response to Pam3-CysAlaGly occurred more slowly than Pam$ysSer( Lys)*-induced aggregation, and Pam$ysAlaGly was less effective. Figure 1B shows a concentration-response relationship of the effect of Pam&ysSer(Lys), on platelet aggregation. The effectiveness and the velocity of the lipopeptide-induced platelet aggregation increased with increasing concentrations of Pam&ysSer(Lys)+ Platelet aggregation in response to Pam$ysSer(Ly& and thrombin was markedly reduced in the absence of calcium, indicating that aggregation induced by these stimuli is dependent on the presence of extracellular calcium (Fig. 1C) .
To test the effect of lipopeptides on the release of mediators from platelets, platelets were loaded with [3H]serotonin, and [3H]serotonin release was measured after addition of stimuli ( Pam3CysSer (Lys)4 was able to induce platelet activation. Neither the lipid moieties Pam&ys and Pam&ysPEG nor the hexapeptide CysSer(Lysj4 led to platelet aggregation or serotonin release in human platelets (Table 1 ). Each substance was tested at concentrations to 100 p,M (data not shown).
To study the relevance of lipopeptide-induced tyrosine phosphorylation,
we assessed the effect of the tyrosine kinase inhibitor genistein (1) on lipopeptide-induced platelet activation. Genistein has been shown to inhibit activation of platelets induced by different stimuli (6,2). Figure 6A shows the effect of genistein (30 and 100 PM) on Pam&ysSer(Lysj4-and thrombin-induced tyrosine phosphorylation. Preincubation of platelets with 100 PM genistein blocked the effect of Pam&!ysSer(Ly& and considerably inhibited the effect of thrombin on tyrosine phosphorylation.
Genistein at the same concentration led to the marked inhibition of lipopeptide-and thrombin-induced platelet aggregation (Fig. 6 , B and C, respectively) and serotonin release (Fig. 6D) . In all cases the inhibitory effect of genistein toward Pam3-CysSer(Lys)4-induced responses was more pronounced than toward thrombin effects. Although inhibition of aggregation induced by both stimuli was almost complete after preincubation of platelets with 300 FM genistein, 300 p,M genistein by itself released some (Fig. 7) . The inhibitory effects of cicaprost toward the action of thrombin were more pronounced than the inhibitory effects toward Pam3CysSer(Ly&-induced platelet activation. Because stimulation of CAMP production by different mechanisms is known to inhibit tyrosine phosphorylation and [Ca2+l, elevation induced by different stimuli in platelets (10,22,31), we additionally tested the effect of cicaprost on tyrosine phosphorylation and [Ca2+]i elevation induced by Pam3CysSer(Ly& and thrombin (Fig. 7, C and D) . Although thrombininduced tyrosine phosphorylation was totally abolished by cicaprost, the rise in [Caz+]i produced by thrombin and the effects of Pam3CysSer(LysJ4 on [Ca2+]i and tyrosine phosphorylation were markedly reduced by the prostacyclin analogue cicaprost.
DISCUSSION
Synthetic lipopeptide analogues of bacterial lipoprotein, which constitutes a major component of the outer membrane of gram-negative bacteria, are well known activators of B-lymphocytes, macrophages, and neutrophils (3, 12, 28). The data presented here indicate that lipopeptides also activate human platelets. The activation of platelets was examined by studying the effect of lipopeptides on the main platelet responses to stimuli, i.e., the aggregation of platelets and the release of granule content measured as serotonin secretion from [3H]serotonin-loaded platelets. The lipopeptide Pam3-CvsSer(LvsId rapidly induced aggregation of platelets and secretion of serotonin from platelets ( Figs. 1 and 2) . Effects could be observed at Pam3CysSer(Lys), concentrations of < 1 FM. Half-maximal and maximal effects occurred at concentrations of 2-3 and lo-30 PM, respectively ( Figs. 1 and 2) . The maximum response of Pam3CysSer(Lys)4 was of similar magnitude to that obtained using 1.5 U/ml thrombin, a potent platelet stimulus. Platelet activation in response to Pam3Cys-Ser(Lys), differed from activation induced by thrombin, in that it occurred significantly earlier.
To exclude the possibility that platelet activation was dependent on the positively charged lysine residues of Pam3CysSer(Lys)4 and to elucidate which part of the lipopeptide molecule is necessary for its biological activity, Pam3CysPEG, the lipopeptide Pam3CysAlaGly, and [Ca2+l, was determined as described in Fig. 3 and c In all experiments shown, Cel l s were preincubated for 5 min with cicaprost. (Fig. 4 and Table 1 ). In addidependent manner. Elevation of [Ca2+]i and stimulation tion, high concentrations of dilysine (applied at of tyrosine phosphorylation were achieved with halfconcentrations to 1 mM) were without any effect on maximal and maximal concentrations of N 2-3 and 10 platelet aggregation and serotonin secretion (data not PM Pams,C!ysSer(Lys)a, respectively (Figs. 3 and 4) . The shown). Taken together, this indicates that the characconcentrations are similar to those needed for platelet teristic lipid moiety of lipopeptides, consisting of one aggregation and secretion ( Figs. 1 and 2) . The lipopepamide-linked and two ester-linked fatty acids attached tide PamsCysAlaGly also induced tyrosine phosphorylato S-(2,3-dihydroxypropyl)-cysteine, is necessary but tion of proteins with molecular masses identical to those not sufficient for platelet activation by lipopeptides and found after incubation with PamsCysSer(Lys)( (Fig. 4) for platelet activation is demonstrated by the finding that the tyrosine kinase inhibitor genistein, which largely inhibited tyrosine phosphorylation in response to PamSCysSer(Lys)d and thrombin, inhibited platelet aggregation and serotonin secretion in a concentration-dependent manner in response to both stimuli (Fig. 6 ). This is in line with earlier studies showing that tyrosine phosphorylation is implicated in platelet aggregation and secretion of serotonin (17, 26).
In addition, tyrosine phosphorylation of a subset of proteins phosphorylated on tyrosine residues in the course of platelet activation has been shown to be dependent on the activation of glycoprotein IIb-IIIa and subsequent fibrinogen binding (8, 10) .
Platelet activation by Pam&ysSer( Lys)4 also resembled thrombin-induced activation with regard to its dependence on the presence of extracellular calcium. Although tyrosine phosphorylation induced by both stimuli was only slightly inhibited in the absence of extracellular calcium (data not shown), platelet aggregation and [Ca"+]i elevation were markedly reduced in the absence of extracellular calcium (Figs. 1 and 3) . Similarly, elevation of the intracellular CAMP concentration via the prostacyclin receptor by cicaprost inhibited both Pam&ysSer( Ly&-and thrombin-induced platelet activation (Fig. 7) . These data indicate that lipopeptideinduced platelet activation is susceptible to the action of a physiological platelet inhibitor.
Although the effects of both thrombin and PamyCysSer(Ly& are mediated at least in part by similar or identical mechanisms, it is obvious that the activation of platelets by lipopeptide and by thrombin exhibit slightly different susceptibilities toward the action of cicaprost and genistein and toward the removal of extracellular calcium. Genistein more effectively inhibited the effects of Pam$ysSer(Ly& (Fig 6) , and cicaprost more effectively inhibited the effects of thrombin (Fig. 7) . In addition, the thrombin-induced aggregation was more susceptible to the removal of extracellular calcium than the lipopeptide-induced aggregation (Fig. 1 ). So far, it is not clear whether lipopeptides activate platelets via a surface receptor or whether lipopeptides exert their effects independently of a surface receptor. The latter possibility appears to be conceivable, since studies carried out by electron energy loss spectroscopy (32) indicate that lipopeptide can quickly enter the cell. Because lipopeptides lead to the activation of early signal transduction pathways identical to thrombin, the site of a receptor-independent platelet activation by lipopeptides can be assumed to be located at an early step of the pathways leading to platelet activation. The direct activation of guanine nucleotide-binding proteins (G proteins) b y 1 ipopeptides may represent a possible mechanism for the lipopeptide effects (28). In any case, the molecular site of lipopeptide action remains to be elucidated.
Whether lipoprotein or lipopeptides, which are a main component of the outer membrane of gram-negative bacteria and which occur in murein-bound and free form, can be released from bacteria in considerable quantities and whether they may play a pathophysiological role in inflammatory processes due to gram-negative bacteria or in gram-negative sepsis is as yet not known. The direct activation of platelets by lipopeptides could contribute to the known platelet activation in the course of endotoxemia (15, 18, 33). However, this speculation needs further support by the use of in vivo models. Interestingly, lipid A, which is also derived from gramnegative bacteria and which shows some structural similarities to lipopeptides (2 amide-and 2 ester-linked hydroxy fatty acids to a glucosamine backbone in lipid A vs. 2 ester-and 1 amide-linked palmitic acids in lipopeptides), has also been shown to activate platelets (11, 24, 25) In 
